How does Zilucoplan work?

Zilucoplan (Zilucoplan) is an innovative therapeutic drug that targets the complement system. It mainly interferes with the disease process related to terminal complement activation by inhibiting the complement C5 protein. It is especially used to treat chronic autoimmune diseases such as myasthenia gravis (AChR-Ab+ MG; rare disease ) with positive acetylcholine receptor antibodies. This drug was developed by UCB Company and is an important new member in the current field of complement pathway targeting drugs. Its mechanism of action focuses on regulating the complement cascade reaction of the body's innate immune system and cutting off the key chains that cause cell damage and neuromuscular conduction disorders.

The mechanism of zeleptide can start from the physiological basis of the complement cascade reaction. The complement system is part of the body's natural immunity and plays a role in marking foreign invading substances, initiating inflammatory responses and clearing immune complexes. Among them, C5 protein is a core component of the complement cascade and will be cleaved into C5a and C5b after being stimulated. C5a is a powerful inflammatory mediator that can cause leukocyte chemotaxis, local tissue edema and inflammatory activation, while C5b is the starting point of the membrane attack complex (MAC, C5b-9). MAC can insert into the cell membrane and form holes, leading to cell lysis and death.

In antibody-mediated autoimmune diseases such as myasthenia gravis, the abnormally activated complement system attacks the patient's own neuromuscular junctions, especially targeting acetylcholine receptors (AChR), triggering an inflammatory cascade, ultimately causing nerve signal transmission disorders, muscle weakness and even respiratory failure. The mechanism of action of zeleptide is to block this pathological cascade process: as a synthetic peptide complement C5 inhibitor, it can specifically bind to the C5 protein and prevent it from being cleaved into C5a and C5b, thus inhibiting terminal activation of complement and the formation of MAC. This inhibitory effect can not only reduce the inflammatory response, but also protect tissue cells from being destroyed by complement.

Different from traditionalC5 inhibitors such as Eculizumab, zeleptide is administered by subcutaneous injection and has a small molecular structure, better tissue penetration and ease of administration. Its daily subcutaneous injection method not only simplifies the treatment process, but also avoids the inconvenience caused by intravenous injection, while maintaining a relatively stable blood concentration and reducing fluctuations in drug efficacy. More importantly, zeleptide does not affect the immune recognition function of upstream complement, so it will not significantly weaken the body's basic immune response to infection, making its immune safety more advantageous in long-term use.

In addition, Zeleptide’s selective inhibition of terminal complement activation makes it highly targeted and reduces the risk of side effects caused by systemic immunosuppression. For example, does not interfereT cell and B cell functions will not broadly inhibit white blood cell activity. This allows the drug to retain the patient's normal immune defense capabilities as much as possible while controlling the symptoms of the disease. It is an important representative of precision immunological drug treatment in recent years.

In summary, zeleptide inhibits the terminal cascade reaction of the complement system and the release of inflammatory mediators by highly selectively inhibiting the C5 protein, thereby interrupting the autoimmune pathological process and protecting the function of the neuromuscular junction. It is an innovative drug with a clear mechanism, convenient administration, and precise target.

Reference materials:https://www.drugs.com/zilucoplan.html